Previous studies have shown that programmed death-ligand 1 (PD-L1) is often upregulated in breast cancer cells as a mechanism of immune evasion, and PD-L1 blockers have emerged as promising therapeutic agents for the treatment of TNBC [148, 149]. Here, CD274 is linked to breast carcinoma.